Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini, Federica Gigli, Cristina Papayannidis, Michela Rondoni, Felicetto Ferrara, Sara Mastaglio, Annalina Piccioni, Michelina Dargenio, Andrea Corbingi, Francesco Mannelli, Alessandro Cignetti, Patrizia Zappasodi, Maria Paola Martelli, Monia Lunghi, Luana Fianchi, Patrizia Chiusolo, Francesco Grimaldi, Federica Pilo, Carla Fili, Debora Capelli, Massimo Breccia, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Luca Maurillo, Calogero Vetro, Alessandra Sperotto, Caterina Patti, Erika Borlenghi, Federica Lessi, Alessandro Isidori, Raffaele Palmieri, Caterina Alati, Samuele Gatani, Chiara Pessina, Paola Minetto, Carola Riva, Marco Frigeni, Nicola Stefano Fracchiolla, Carla Mazzone, Marco Cerrano, Massimo Bernardi, Michele Gottardi, Roberto Cairoli, Adriano Venditti, Livio Pagano, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2025-4608

Published: 2025

Journal Articles

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Blood (2025) 146 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2025-5127

Published: 2025

Journal Articles

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Blood (2025) 145 (21): 2447–2459.

https://doi.org/10.1182/blood.2024027500

Published: 2025

Includes: Supplemental data

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

Stefania Leone, Francesco Grimaldi, Mara Memoli, Flavia Carriero, Giulia Scalia, Annamaria Vincenzi, Giuseppe Cerciello, Fabrizio Pane, Alessandra Picardi, Giuseppe Terrazzano, Giuseppina Ruggiero, Valentina Rubino

Blood (2024) 144 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2024-210766

Published: 2024

Journal Articles

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Salvatore Palmieri, Roberta Della Pepa, Stefano Rocco, Raffaella Reina, Giuseppe Gaeta, Novella Pugliese, Aldo Leone, Fabio Trastulli, Angela Gravetti, Maria Celentano, Mariangela Pedata, Francesco Grimaldi, Fabrizio Pane, Mario Annunziata

Blood (2024) 144 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2024-210292

Published: 2024

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis

Novella Pugliese, MD, Claudia Giordano, MD, Davide Nappi, Luigia Luciano, MD, Claudio Cerchione, MD PhD, Mario Annunziata, Beniamino Casale, Elena Crisà, MD, Maria Rosaria Villa, Luca Pezzullo, Mariolina Iovine, Marco Picardi, MD, Francesco Grimaldi, MD, Maria Monteverde, Fabrizio Pane

Blood (2018) 132 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2018-99-118986

Published: 2018

Journal Articles

Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Francesco Grimaldi, MD, Pilar Perez-Abellan, Steven Best, PhD, Nicholas Lea, PhD, John Veluchamy, Muhammad Atif, MD, Rosemary Grain, Monica Sen, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Victoria T Potter, MD FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, Judith C.W. Marsh, MD, Linda D Barber, PhD

Blood (2015) 126 (23): 3129.

https://doi.org/10.1182/blood.V126.23.3129.3129

Published: 2015

Journal Articles

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Francesco Grimaldi, MD, Linda D Barber, PhD, Pilar Perez-Abellan, MSc, Rosemary Grain, Victoria T Potter, MD FRCPA, FRACP, Austin Kulasekararaj, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Judith C Marsh, MD

Blood (2014) 124 (21): 1594.

https://doi.org/10.1182/blood.V124.21.1594.1594

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

First-Line Daratumumab-Based Regimens in Multiple Myeloma Patients Aged 65-70 Years: A Pilot Real-World Study on Efficacy and Safety

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only